AstraZeneca, Daiichi notch blockbuster FDA nod for breast cancer med Enhertu
admin 23rd December 2019 Uncategorised 0For metastatic breast cancer patients who try and fail on multiple treatments, finding options to manage disease is a difficult proposition. AstraZeneca and Daiichi Sankyo hoped their antibody-drug conjugate could help that tough-to-treat population––and the FDA agreed to give it a shot despite a shaky safety profile.
More: AstraZeneca, Daiichi notch blockbuster FDA nod for breast cancer med Enhertu
Source: fierce